Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Alzamend Neuro | AL001 | dementia related to mild, moderate and severe cognitive impairment associated with Alzheimer’s disease | IND approved by the FDA |
| Kronos Bio | lanraplenib | relapsed/refractory and newly diagnosed acute myeloid leukemia | IND approved by the FDA |
| NeoImmuneTech | NT-I7 (efineptakin alfa) | Kaposi sarcoma in patients with or without HIV infection | IND approved by the FDA |
| I-Mab | efineptakin alfa | advanced solid tumors | IND approved by the Center for Drug Evaluation of the China National Medical Products Administration for a phase 2 trial |
| Arcturus Therapeutics | ARCT-810 | ornithine transcarbamylase deficiency | clinical trial authorized by the UK Health Research Authority |
| Synchron | Stentrodemotor neuroprosthesis | severe paralysis | Investigational Device Exemption approved by the FDA |
| Clarity Pharmaceuticals | 64/67Cu SAR-bisPSMA theranostic | identification and treatment of metastatic castrate-resistant prostate cancer | initiation of phase 1 trial |
| Disc Medicine | DISC-0974 | anemia of inflammation | initiation of phase 1 trial |
| Mersana Therapeutics | upifitamab rilsodotin (XMT-1536) | platinum-sensitive ovarian cancer | initiation of phase 1 trial |
| Karyopharm | XPOVIO in combination with Jakafi | patients with treatment-naïve myelofibrosis | initiation of phase 1/2 trial |
| MediWound | MW005 | low-risk basal-cell carcinoma | initiation of phase 1/2 trial |
| XyloCor Therapeutics | XC001 (encoberminogene rezmadenovec) | refractory angina | initiation of phase 2 portion of phase 1/2 trial |
| HutchMed AstraZeneca |
Orpathys (savolitinib) | advanced or metastatic MET-amplified gastric cancer or adenocarcinoma of the gastroesophageal junction | initiation of phase 2 trial |
| Karyopharm | XPOVIO in combination with Keytruda | locally advanced or metastatic melanoma that is resistant to initial checkpoint inhibitor therapy | initiation of phase 2 trial |
| AbbVie | Dalvance (dalbavancin) | acute bacterial skin and skin structure infections in pediatric patients from birth | approved by the FDA for expanded indication |
| AstraZeneca | Bydureon BCise (exenatide extended-release) | type 2 diabetes in children 10 years of age and older | approved by the FDA for expanded indication |
| Merck | Keytruda | high-risk early-stage triple-negative breast cancer | approved by the FDA for new indication |
| BeiGene | Brukinsa (zanubrutinib) | mantle-cell lymphoma | approved in Canada |
Upcoming Events
-
25May
-
28Jun
-
16Oct
